Outcome of the Board meeting held on today 04th June, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Novelix Pharmaceuticals' board approved the issue and allotment of 12,00,000 equity shares to non-promoters on a preferential basis at Rs. 57 per share (face value Rs. 10 + premium of Rs. 47), aggregating to approximately Rs. 6.84 crore. The shares will be allotted to 13 named non-promoter allottees, subject to shareholder and regulatory approvals under Section 42 and 62 of the Companies Act, 2013 and SEBI ICDR Regulations. An Extra-Ordinary General Meeting (EGM) has been scheduled for July 1, 2026 via video conferencing to seek member approval, with a cut-off date of June 24, 2026 for e-voting eligibility. A Practicing Company Secretary has been appointed as scrutinizer for the e-voting process. The board meeting commenced at 5:00 PM and concluded at 9:15 PM on June 4, 2026.
This is a modest capital raise of about Rs. 6.84 crore through preferential allotment to non-promoter investors, which will dilute existing shareholders' stakes slightly. Bringing in multiple new non-promoter investors may be viewed positively as it broadens the shareholder base, though the small size of the raise limits any major impact on the stock.